Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Collegium Pharmaceutical, Inc. (COLL) vs Cronos Group Inc. (CRON)

Collegium Pharmaceutical, Inc. and Cronos Group Inc. are both Drug Manufacturers Specialty & Generic companies. Cronos Group Inc. is the larger, with a market value of $1.2B against $737.1M — 1.7× the size. Collegium Pharmaceutical, Inc. trades at the lower P/E: 14.7× against 16.7×. Cronos Group Inc. grew revenue faster over the last twelve months: 37.5% against 14.3%. Cronos Group Inc. has the higher net margin (20.9% vs 5.93%) and the lower return on invested capital (−0.34% vs 7.85%). Across the 21 metrics below, Collegium Pharmaceutical, Inc. leads on 13 and Cronos Group Inc. on 8.

Valuation

Metric COLL CRON Drug Manufacturers Specialty & Generic median
P/E 14.73 16.70 20.14
P/S 0.90 6.97 2.25
P/B 2.34 1.12 1.90
Price to free cash flow n/m 25.24 16.54
EV/EBITDA 4.29 36.04 12.29
EV/Sales 2.07 2.53 2.56
Earnings yield 6.79% 5.99% (2.99%)
Free cash flow yield (5.46%) 3.96% 0.00%

Profitability

Metric COLL CRON Drug Manufacturers Specialty & Generic median
Gross margin 60.02% 45.86% 53.94%
Operating margin 19.48% (0.96%) 0.00%
Net margin 5.93% 20.91% 0.00%
Free cash flow margin 40.62% 27.61% 0.00%
Return on equity 17.61% 3.33% (0.40%)
Return on assets 2.57% 3.18% (3.32%)
Return on invested capital 7.85% (0.34%) 0.00%

Growth

Metric COLL CRON Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 14.31% 37.46% 10.01%
EPS growth (last fiscal year) (6.99%) (118.18%) —
Revenue growth, 5-year CAGR 20.28% 25.70% 6.74%
Net income growth, 5-year CAGR 18.64% 0.00% 0.00%

Health

Metric COLL CRON Drug Manufacturers Specialty & Generic median
Debt to equity 3.50 0.00 0.05
Current ratio 1.03 16.18 2.31
Net debt to EBITDA 1.00 337.10 0.85

Dividend

Metric COLL CRON Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric COLL CRON Drug Manufacturers Specialty & Generic median
Market cap 737.06m 1.22b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack